Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709771 · ClinicalTrials.gov registry record
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03709771: Clinical Trial study, sponsored by Vanderbilt University Medical Center.
NCT03709771 is a clinical trial that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03709771 was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.
Primary Outcome
Mean 24 hour blood pressure from ambulatory 24 hour recording
Interventions
- DIAGNOSTIC_TEST Ambulatory Blood Pressure Measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2020-10-01 |
Why NCT03709771 stopped before completion
NCT03709771 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ambulatory Blood Pressure Measurement is the first listed.
NCT03709771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03709771 about?
NCT03709771 is a clinical study titled "Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease". The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.
What is the current status of trial NCT03709771?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-01-09. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT03709771?
The interventions under investigation include: Ambulatory Blood Pressure Measurement (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03709771?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI